Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders

Achiron A, Gornish M, Melamed E. Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia. Stroke 21: 817–819, 1990 Agnelli G, Gresele P, De Cunto M, Gallai V, Nenci G. Tranexamic acid, IUCD and fatal cerebral arterial thrombosis. British Journal of Obstetrics and Gynaecology 89: 681–682, 1982 Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstetrica Gynecologica Scandinavica 67: 645–648, 1988 Bergqvist A, Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. British Journal of Obstetrics and Gynaecology 90: 255–258, 1983 Bishop PMF and de Almeida JC. Treatment of functional menstrual disorders with norethisterone. British Medical Journal 1: 1103–1105, 1960 Bonnar J, Sheppard BL, Dockeray CJ. The haemostatic system and dysfunctional uterine bleeding. Research and Clinical Forums 5: 27–36, 1983 Cameron IT, Haining RH, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology 76: 85–88, 1990 Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 34: 99–110, 1987 Chimbira TH, Anderson AB, Cope E, Turnbull AC. Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with menorrhagia. British Journal of Obstetrics and Gynaecology 87: 330–336, 1980b Chimbira TH, Anderson AB, Naish C, Cope E, Turnbull AC. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. British Journal of Obstetrics and Gynaecology 87: 1152–1158, 1980a Chimbira TH, Anderson AB, Turnbull AC. Relation between measured menstrual blood loss and patient’s subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. British Journal of Obstetrics and Gynaecology 87: 603–609, 1980c Chimbira TH, Cope E, Anderson AB, Bolton FG. The effect of danazol on menorrhagia, coagulation mechanisms, haemato-logical indices and body weight. British Journal of Obstetrics and Gynaecology 86: 46–50, 1979 Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. Journal of Obstetrics and Gynaecology in the British Commonwealth 78: 933–939, 1971 Conyngham RB. Norethisterone in menorrhagia. New Zealand Medical Journal 64: 697–701, 1965 Coulter A, McPherson K, Vessey M. Do British women undergo too many or too few hysterectomies?. Social Sciences and Medicine 27: 987–994, 1988 Dockeray CJ. The medical treatment of menorrhagia. In Chamberlain (Ed.) Contemporary obstetrics and gynaecology, pp. 299–314, Butterworths, London, 1988 Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. British Journal of Obstetrics and Gynaecology 96: 840–844, 1989 Foss GL. Clinical experience with norethisterone and norethisterone acetate. British Medical Journal 2: 1187–1191, 1960 Fraser IS. The treatment of menorrhagia with mefenamic acid. Research and Clinical Forums 5: 93–99, 1983 Fraser IS. Treatment of dysfunctional uterine bleeding with danazol. Australia and New Zealand Journal of Obstetrics and Gynaecology 25: 224–226, 1985 Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. American Journal of Obstetrics and Gynecology 149: 788–793, 1984 Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of menorrhagia with mefenamic acid. Obstetrics and Gynecology 61: 109–112, 1983 Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstetrics and Gynecology 58: 543–551, 1981 Grant JM, Hussein IY. An audit of abdominal hysterectomy over a decade in a district hospital. British Journal of Obstetrics and Gynaecology 91: 73–77, 1984 Hagenfeldt K. The role of prostaglandins and allied substances in uterine haemostasis. Contraception 36: 23–35, 1987 Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss, a population study. Acta Obstetrica et Gynecologica Scan-dinavica 45: 320–351, 1966 Hallberg L, Nilsson L. Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation 16: 244–248, 1964 Harrison RF, Campbell S. A double-blind trial of ethamsylate in the treatment of primary and intrauterine-device menorrhagia. Lancet 2: 283–285, 1976 Haynes PJ, Flint AP, Hodgson H, Anderson AB, Dray F, et al. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. International Journal of Gynaecology and Obstetrics 17: 567–572, 1980 Jeppsson S, Mellquist P, Rannevik G. Short-term effects of dan-azol on endometrial histology. Acta Obstetrica et Gynecologica Scandinavica 123: (Suppl.) 41–44, 1984 Loffer FD. Hysteroscopy with selective endometrial sampling compared with D & C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstetrics and Gynecology 73: 16–20, 1989 Lumsden MA. Dysmenorrhoea. In Baird & Michie (Eds) Mechanism of menstrual bleeding, pp. 195–213, Raven Press, New York, 1985 MacKenzie IZ, Bibby JG. Critical assessment of dilatation and curettage in 1029 women. Lancet 2: 566–568, 1978 Makarainen L, Ylikorkala D. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. British Journal of Obstetrics and Gynaecology 93: 974–978,1986 Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the LHRH analogue buserelin in premenopausal women. Clinical Endocrinology 29: 45–51, 1988 Metcalf MG. Incidence of ovulatory cycles in women approaching the menopause. Journal of Biosocial Science 11: 39–48, 1979 Mishell Jr DR. Noncontraceptive health benefits of oral steroidal contraceptives. American Journal of Obstetrics and Gynecology 142: 809–816, 1982 Nilsson L, Rybo G. Treatment of menorrhagia. American Journal of Obstetrics and Gynecology 110: 713–720, 1971 Rees MCP, Anderson AB, Demers LM, Turnbull AC. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. British Journal of Obstetrics and Gynaecology 91: 673–680, 1984 Rees MCP, Canete-Soler R, Lopez Bernai A, Turnbull AC. Effects of fenamates on prostaglandin E receptor binding. Lancet 2: 541–542, 1988 Rees MCP, Di Marzo V, Tippins JR, Morris HR, Turnbull AC. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. Journal of Endocrinology 113: 291–295, 1987 Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology 91: 913–916, 1984 Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology 88: 434–442, 1981 Tauber PF, Kloppel A, Goodpasture JC, Burns J, Ludwig H, et al. Reduced menstrual blood loss by release of an antifibrolytic agent from intrauterine contraceptive devices. American Journal of Obstetrics and Gynaecology 140: 322–328, 1981 Thiery M, Van der Pas H, Delbarge W, Van Kets H. The levonorgestrel intrauterine device. Geburtshilfe und Frauenheilk-und 49: 186–188, 1898 Treolar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. International Journal of Fertility 12: 77–126, 1967 Vargyas JM, Campeau JD, Mishell Jr DR. Treatment of menorrhagia with meclofenamate sodium. American Journal of Obstetrics and Gynecology 157: 944–950, 1987